| Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: a systematic review and meta-analysis. | 2024 | Clinical Endocrinology |
| Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2024 | International Immunopharmacology |
| Assessing patient risk, benefit, and outcomes in drug development: a decade of lenvatinib clinical trials: a systematic review. | 2024 | Targeted Oncology |
| Lenvatinib versus atezolizumab plus bevacizumab in the first-line treatment for unresectable hepatocellular carcinoma: a meta-analysis of real-world studies. | 2024 | Targeted Oncology |
| Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies. | 2024 | Frontiers in Endocrinology |
| Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis. | 2024 | Frontiers in Oncology |
| Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis. | 2024 | Frontiers in Immunology |
| Atezolizumab plus bevacizumab versus lenvatinib for hepatocellular carcinoma: a systematic review and meta-analysis. | 2024 | Journal of Clinical Pharmacology |
| Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma. | 2024 | Urologic Oncology |
| Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. | 2024 | Cancer Immunology, Immunotherapy |
| Transarterial chemoembolization combined with lenvatinib for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. | 2024 | Oncology |
| Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. | 2024 | European Journal of Gastroenterology & Hepatology |
| Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Journal of Cancer Research and Clinical Oncology |
| Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Journal of Cancer Research and Clinical Oncology |
| Immunotherapy and targeted therapies efficacy in thymic epithelial tumors: a systematic review. | 2023 | Biomedicines |
| Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2023 | Frontiers in Pharmacology |
| Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Clinical and Experimental Hepatology |
| Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: a meta-analysis. | 2023 | Medicine |
| First-line systemic treatment for hepatocellular carcinoma: a systematic review and network meta-analysis. | 2023 | Heliyon |
| Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis. | 2023 | World Journal of Surgical Oncology |
| Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity. | 2023 | Frontiers in Oncology |
| Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. | 2023 | European Journal of Clinical Pharmacology |
| Metabolic adverse events of multitarget kinase inhibitors: a systematic review. | 2023 | Endocrine |
| Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Frontiers in Oncology |
| Safety and efficacy of TACE + lenvatinib in treating advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Journal of Gastrointestinal and Liver Diseases |
| Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Medicine |
| First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. | 2023 | Cancer Immunology, Immunotherapy |
| Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis. | 2023 | Frontiers in Oncology |
| First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. | 2023 | Cochrane Database of Systematic Reviews |
| Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2023 | Critical Reviews in Oncology/Hematology |
| The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: a systematic review. | 2023 | Frontiers in Oncology |
| A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately? | 2023 | Current Opinion in Oncology |
| Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus: a systematic review and meta-analysis. | 2023 | Current Oncology |
| Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Journal of Cancer Research |
| Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Journal of Cancer |
| Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis. | 2023 | Cost Effectiveness and Resource Allocation |
| Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: a systematic review and network meta-analysis of safety. | 2023 | Cancer Medicine |
| Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis. | 2023 | Frontiers in Oncology |
| Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Clinics and Research in Hepatology and Gastroenterology |
| Impact of post-progression survival on outcomes of lenvatinib treatment for unresectable hepatocellular carcinoma: a systematic review and retrospective cohort study. | 2022 | Anticancer Research |
| IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: a structured systematic review over time. | 2022 | Seminars in Oncology |
| Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network meta-analysis of phase III trials. | 2022 | European Journal of Cancer |
| Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: a network meta-analysis of randomized sorafenib-controlled trials. | 2022 | Hepatology Communications |
| Systemic therapies for metastatic renal cell carcinoma in the second-line setting: a systematic review and network meta-analysis. | 2022 | Medicine |
| Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis. | 2022 | Frontiers in Pharmacology |
| The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. | 2022 | International Immunopharmacology |
| Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis. | 2022 | Frontiers in Endocrinology |
| Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. | 2022 | Therapeutic Advances in Medical Oncology |
| New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | Cancer Treatment Reviews |
| Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | The Journal of Urology |
| Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | European Urology Open Science |
| Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. | 2022 | Immunotherapy |
| First- and second-line treatments for patients with advanced hepatocellular carcinoma in China: a systematic review. | 2022 | Current Oncology |
| Incidence and risk of hypertension with lenvatinib in the treatment of solid tumors: an updated systematic review and meta-analysis. | 2022 | The Journal of Clinical Hypertension |
| Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: a meta-analysis. | 2022 | Frontiers in Oncology |
| Lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2022 | Cancers |
| Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2022 | The Journal of Urology |
| How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. | 2022 | Frontiers in Oncology |
| First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials. | 2021 | Frontiers in Oncology |
| First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2021 | European Urology Oncology |
| Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. | 2021 | Cancer Treatment Reviews |
| Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). | 2021 | Gastroenterology |
| Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: a systematic review and meta-analysis of clinical trials. | 2021 | Clinical Endocrinology |
| Non-surgical management of advanced hepatocellular carcinoma: a systematic review by Cancer Care Ontario. | 2021 | Canadian Liver Journal |
| Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. | 2021 | Journal of Cancer Research and Clinical Oncology |
| Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. | 2021 | Current Opinion in Urology |
| Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. | 2021 | World Journal of Gastroenterology |
| The efficacy and safety of lenvatinib in the treatment of solid tumors: an up-to-date meta-analysis. | 2021 | Future Oncology |
| Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. | 2021 | International Immunopharmacology |
| A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2021 | American Journal of Translational Research |
| Efficacy of first-line systemic chemotherapy and multikinase inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2021 | Frontiers in Oncology |
| Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. | 2021 | Journal of Hepatocellular Cancer |
| Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. | 2021 | Liver Cancer |
| Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. | 2021 | Critical Reviews in Oncology/Hematology |
| Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: a systematic review and meta-analysis of clinical trials. | 2021 | Clinical Endocrinology |
| Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. | 2021 | Journal of the National Cancer Institute |
| Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. | 2021 | World Journal of Gastroenterology |
| A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. | 2021 | Expert Review of Anticancer Therapy |
| Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. | 2020 | Endocrine Journal |
| Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systematic review. | 2020 | Seminars in Oncology |
| First-line targeted therapies of advanced hepatocellular carcinoma: a Bayesian network analysis of randomized controlled trials. | 2020 | PLoS One |
| Anti-tumor activity and safety of multikinase inhibitors in advanced and/or metastatic thyroid cancer: a systematic review and network meta-analysis of randomized controlled trials. | 2020 | Hormone and Metabolic Research |
| Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2020 | JAMA Oncology |
| Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. | 2020 | Health Technology Assessment |
| Relative efficacy of systemic treatments for patients with advanced hepatocellular carcinoma according to viral status: a systematic review and network meta-analysis. | 2019 | Target Oncology |
| Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma. | 2019 | PLoS One |
| A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. | 2019 | BMC Cancer |
| Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. | 2019 | BMJ Open |
| Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis | 2019 | Cancer Management and Research |
| Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials | 2019 | Journal of Clinical Gastroenterology |
